+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risks and benefits of Helicobacter pylori eradication: current status



Risks and benefits of Helicobacter pylori eradication: current status



Canadian Journal of Gastroenterology 16(1): 57-62



In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 047278722

Download citation: RISBibTeXText

PMID: 11826340

DOI: 10.1155/2002/202961


Related references

Helicobacter pylori eradication: current status. Terapevticheskii Arkhiv 85(2): 73-75, 2013

Current Status of the Third-Line Helicobacter pylori Eradication. Gastroenterology Research and Practice 2018: 6523653-6523653, 2018

Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clinical and Experimental Gastroenterology 5: 151-157, 2012

Helicobacter pylori eradication therapy with omeprazole and amoxicillin: current status. Leber, Magen, Darm 24(6): 228-232, 1994

Current status of Helicobacter pylori eradication therapy. Significance of roxithromycin. Fortschritte der Medizin 115(27): 54-55, 1998

Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey. Digestion 92(2): 55-59, 2015

Clinical and economic effects of immediate Helicobacter pylori eradication for patients with documented peptic ulcer disease but unknown Helicobacter pylori status. Gut 39(SUPPL 2): A31, 1996

Helicobacter pylori status and symptom assessment 5 years after Helicobacter pylori eradication. Gastroenterology 120(5 Supplement 1): A 586, April, 2001

Current status of treatment for patients with idiopathic thrombocytopenic purpura in the Hokkaido area (evaluation of Helicobacter pylori eradication). Japanese Journal of Clinical Hematology 45(7): 539-545, 2004

Who benefits from Helicobacter pylori eradication?. Bmj 332(7535): 187-188, 2006

Benefits of Helicobacter pylori eradication in hemodialysis patients. Nephrology Dialysis Transplantation 16(6): A145, June, 2001

Validity of a Helicobacter pylori stool antigen assay for the assessment of H. pylori status following eradication therapy. European Journal of Gastroenterology & Hepatology 13(6): 673-676, 2001

Assessing the risks and benefits of treating Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2(3): 141-147, 2009

Eradication of Helicobacter pylori: current perspectives. Expert Opinion on PharmacoTherapy 3(8): 1031-1038, 2002

Current Helicobacter pylori eradication regimens. Acta Endoscopica 28(3): 205-212, 1998